2000
DOI: 10.1177/009286150003400317
|View full text |Cite
|
Sign up to set email alerts
|

Pediatric Drug Development: The International Conference on Harmonization Focus on Clinical Investigations in Children

Abstract: Recent public awareness and scientific advances have launched a reversal in the historical trend to virtually ignore the importance of obtaining reliable data from pediatric patients during the process of drug development. The need for well-designed clinical trials in children is now clearly recognized, and a few regulatory bodies have addressed the requirements for the conduct of these trials. Global consensus on the unique issues related to pediatric trials, howevec has been lacking. The International Confer… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2003
2003
2017
2017

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 44 publications
0
1
0
Order By: Relevance
“…If this approach is taken, adult PK data should be available to plan the pediatric studies." 108 Since adoption of that guideline, pediatric drug development has been enhanced by advancements in several areas of general adult drug development, without a parallel development of the harmonized guidance in these areas. A July 2014 addendum to address new scientific and technical advances in pediatric drug development added that extrapolation of data in pediatric drug development is an area "where technical and regulatory assessments and consensus is evolving" acknowledging that "there are differences in how regulatory authorities define extrapolation and consider limitations to the utilisation of extrapolated data."…”
Section: Regulatory Considerations For Extrapolationmentioning
confidence: 99%
“…If this approach is taken, adult PK data should be available to plan the pediatric studies." 108 Since adoption of that guideline, pediatric drug development has been enhanced by advancements in several areas of general adult drug development, without a parallel development of the harmonized guidance in these areas. A July 2014 addendum to address new scientific and technical advances in pediatric drug development added that extrapolation of data in pediatric drug development is an area "where technical and regulatory assessments and consensus is evolving" acknowledging that "there are differences in how regulatory authorities define extrapolation and consider limitations to the utilisation of extrapolated data."…”
Section: Regulatory Considerations For Extrapolationmentioning
confidence: 99%